RESUMEN
In this study, we report the development and evaluation of soy lecithin-chitosan hybrid nanoparticles to improve the oral bioavailability of raloxifene hydrochloride. The nanoparticles were formed by interaction of negatively charged soy lecithin with positively charged chitosan. The ratio of soy lecithin to chitosan was critical for the charge, and hence the size of the nanoparticles. The optimal soy lecithin to chitosan ratio was 20:1 to obtain nanoparticles with particle size of 208 ± 3 nm, a ζ-potential of 36 ± 2 mV and an entrapment efficiency of 73 ± 3%. The nanoparticles were also characterized by differential scanning calorimetry and FT-IR spectrophotometer. In-vitro drug release was assessed using dialysis bag method in pH 7.4 buffer. The drug loaded nanoparticles did not cause significant reduction in the cell viability at low doses. Pharmacokinetic studies in female Wistar rats showed significant improvement (~4.2 folds) in the oral bioavailability of the drug when loaded into nanoparticles. Further, the modified everted gut sac study showed that these nanoparticles are taken up by active endocytic processes in the intestine. The ex-vivo mucoadhesion studies proved that the nanoparticles get bound to the mucus layer of the intestine, which in turn correlates with reduced excretion of the drug in faeces. In conclusion, the proposed nanoparticles appear promising for effective oral delivery of poorly bioavailable drugs like raloxifene hydrochloride.
Asunto(s)
Quitosano , Nanopartículas , Clorhidrato de Raloxifeno , Administración Oral , Animales , Disponibilidad Biológica , Portadores de Fármacos , Femenino , Lecitinas , Tamaño de la Partícula , Ratas , Ratas Wistar , Espectroscopía Infrarroja por Transformada de FourierRESUMEN
OBJECTIVE: Drug-induced hepatotoxicity is a major cause of concern in patients receiving HIV/TB co-treatment. Lopinavir (LPV), an anti-HIV drug, shows poor plasma exposure due to hepatic first-pass metabolism. In this study, we investigated the effect of hepatotoxicity on pharmacokinetics of free LPV and LPV-loaded solid lipid nanoparticles (LPV SLNs) in male Wistar rats. METHODS: Hepatic impairment model in rats was developed by injecting CCl4 (i.p., 2 ml/kg). Comparative pharmacokinetic (n = 5) and tissue distribution studies (n = 3) were conducted following oral administration (20 mg/kg) of free LPV and LPV SLNs in normal and hepatic impaired rats. Isolated perfused liver (IPL) model (n = 3) and cycloheximide intervened lymphatic uptake studies (n = 3) were conducted to appreciate disposition pattern of LPV. KEY FINDINGS: In contrary to free LPV, pharmacokinetic results demonstrated no significant (P > 0.05) difference in drug plasma profile of LPV SLNs in normal and impaired rats. IPL model demonstrated trivial role of liver in disposition of LPV SLNs. Tissue distribution studies of SLNs showed higher (P < 0.05) LPV accumulation in lymphoidal organs. Pretreatment of cycloheximide significantly (P < 0.05) reduced AUC and Cmax of LPV SLNs. CONCLUSION: From the results, we conclude that unlike conventional formulations of LPV, disposition characteristics of LPV SLNs were similar both in normal and hepatic impaired rats.
Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Hepatopatías/fisiopatología , Lopinavir/administración & dosificación , Nanopartículas , Administración Oral , Animales , Fármacos Anti-VIH/farmacocinética , Área Bajo la Curva , Modelos Animales de Enfermedad , Lípidos/química , Lopinavir/farmacocinética , Masculino , Ratas , Ratas Wistar , Distribución TisularRESUMEN
A structure based medium throughput virtual screening campaign of BITS-Pilani in house chemical library to identify novel binders of Mycobacterium tuberculosis gyrase ATPase domain led to the discovery of a quinoline scaffold. Further medicinal chemistry explorations on the right hand core of the early hit, engendered a potent lead demonstrating superior efficacy both in the enzyme and whole cell screening assay. The binding affinity shown at the enzyme level was further corroborated by biophysical characterization techniques. Early pharmacokinetic evaluation of the optimized analogue was encouraging and provides interesting potential for further optimization.
Asunto(s)
Adenosina Trifosfatasas/antagonistas & inhibidores , Antituberculosos/farmacología , Girasa de ADN/metabolismo , Descubrimiento de Drogas , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/enzimología , Adenosina Trifosfatasas/química , Antituberculosos/química , Girasa de ADN/química , Ingeniería , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Conformación ProteicaRESUMEN
In this study we explored the pharmaceutically underexploited ATPase domain of DNA gyrase (GyrB) as a potential platform for developing novel agents that target Mycobacterium tuberculosis. In this effort a combination of ligand- and structure-based pharmacophore modeling was used to identify structurally diverse small-molecule inhibitors of the mycobacterial GyrB domain based on the crystal structure of the enzyme with a pyrrolamide inhibitor (PDB ID: 4BAE). Pharmacophore modeling and subsequent inâ vitro screening resulted in an initial hit compound 5 [(E)-5-(5-(2-(1H-benzo[d]imidazol-2-yl)-2-cyanovinyl)furan-2-yl)isophthalic acid; IC50 =4.6±0.1â µm], which was subsequently tailored through a combination of molecular modeling and synthetic chemistry to yield the optimized lead compound 24 [(E)-3-(5-(2-cyano-2-(5-methyl-1H-benzo[d]imidazol-2-yl)vinyl)thiophen-2-yl)benzoic acid; IC50 =0.3±0.2â µm], which was found to display considerable inâ vitro efficacy against the purified GyrB enzyme and potency against the H37 Rv strain of M.â tuberculosis. Structural handles were also identified that will provide a suitable foundation for further optimization of these potent analogues.
Asunto(s)
Adenosina Trifosfatasas/efectos de los fármacos , Antituberculosos/farmacología , Girasa de ADN/efectos de los fármacos , Adenosina Trifosfatasas/química , Animales , Antituberculosos/química , Girasa de ADN/química , Embrión no Mamífero/efectos de los fármacos , Estructura Molecular , Pez Cebra/embriologíaRESUMEN
Lopinavir (LPV)-loaded poly-ε-caprolactone (PCL) nanoparticles (NPs) were prepared by emulsion solvent evaporation technique. Effects of various critical factors in preparation of loaded NPs were investigated. Box-Behnken design (BBD) was employed to optimize particle size and entrapment efficiency (EE) of loaded NPs. Optimized LPV NPs exhibited nanometeric size (195.3 nm) with high EE (93.9%). In vitro drug release study showed bi-phasic sustained release behavior of LPV from NPs. Pharmacokinetic study results in male Wistar rats indicated an increase in oral bioavailability of LPV by 4-folds after incorporation into PCL NPs. From tissue distribution studies, significant accumulation of loaded NPs in tissues like liver and spleen indicated possible involvement of lymphatic route in absorption of NPs. Mechanistic studies using rat everted gut sac model revealed endocytosis as a principal mechanism of NPs uptake. In vitro rat microsomal metabolism studies demonstrated noticeable advantage of LPV NPs by affording metabolic protection to LPV. These studies indicate usefulness of PCL NPs in enhancing oral bioavailability and improving pharmacokinetic profile of LPV.
Asunto(s)
Caproatos/administración & dosificación , Sistemas de Liberación de Medicamentos/métodos , Diseño de Fármacos , Lactonas/administración & dosificación , Lopinavir/administración & dosificación , Nanopartículas/administración & dosificación , Polímeros/administración & dosificación , Administración Oral , Animales , Caproatos/química , Caproatos/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Tracto Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/metabolismo , Lactonas/química , Lactonas/metabolismo , Lopinavir/química , Lopinavir/metabolismo , Masculino , Nanopartículas/química , Nanopartículas/metabolismo , Técnicas de Cultivo de Órganos , Polímeros/química , Polímeros/metabolismo , Ratas , Ratas WistarRESUMEN
In this investigation, we report the use of the pullulan acetate, a hydrophobic derivative of pullulan in the formulation of Lopinavir loaded nanoparticles meant for oral delivery. Pullulan was modified to pullulan acetate by acetylation process in the presence of pyridine; acetylation was confirmed by FT-IR and NMR spectra. Lopinavir, an HIV-protease inhibitor was formulated into nanoparticles of pullulan acetate by the well-known emulsion-solvent-evaporation method. The nanoparticles were tested for particle size, entrapment efficiency, in-vitro drug release and stability. Further, extensive pharmacokinetic and tissue distribution studies were performed in Wistar rats. The results showed that, with our method, we could obtain nanoparticles of â¼197 nm, high entrapment efficiency (â¼75%) and monodisperse nature (PDI<0.2). Stability data showed that the nanoparticles were stable over a period of 3 months. From the pharmacokinetic study data, we found that the relative bioavailability of Lopinavir from nanoparticles was â¼2 folds higher than the free drug. Moreover, the tissue distribution study showed a higher distribution of Lopinavir loaded nanoparticles to lymphoid organs (liver, spleen and lymph nodes that are also important viral reservoirs in HIV infection). Thus, we conclude that Lopinavir loaded nanoparticle could be a superior alternative approach to free Lopinavir in treating HIV infection.
Asunto(s)
Portadores de Fármacos/química , Glucanos/química , Inhibidores de la Proteasa del VIH/administración & dosificación , Lopinavir/administración & dosificación , Nanopartículas/química , Acetilación , Administración Oral , Animales , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/farmacocinética , Lopinavir/farmacocinética , Masculino , Nanopartículas/ultraestructura , Ratas , Ratas Wistar , Distribución TisularRESUMEN
Raloxifene HCl (RLX), a selective oestrogen receptor modulator, has low oral bioavailability (<2%) in humans due to its poor aqueous solubility and extensive first-pass metabolism in gut. In this study, we optimised the method of preparation for poly (ε-caprolactone) (PCL) based nanocapsules of RLX by double emulsion method (w/o/w). A hybrid design approach, Plackett-Burman design followed by rotatable central composite design, was used to arrive at the optimised formulation. The optimised formulation was subjected to in vitro and in vivo evaluation. RLX loaded nanocapsules were spherical in shape with particle size less than 200 nm and high encapsulation efficiency (>80%). RLX-loaded nanocapsules showed 2.1-fold increase in oral bioavailability compared to free RLX. IV pharmacokinetic studies indicated that RLX loaded into nanocapsule had significantly low clearance in comparison with free RLX. Designed nanocapsules showed promise as delivery systems to enhance oral bioavailability and in reducing clearance of raloxifene.
Asunto(s)
Nanocápsulas/química , Poliésteres/química , Clorhidrato de Raloxifeno/administración & dosificación , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Administración Oral , Animales , Femenino , Clorhidrato de Raloxifeno/farmacocinética , Ratas , Ratas Wistar , Moduladores Selectivos de los Receptores de Estrógeno/farmacocinéticaRESUMEN
OBJECTIVES: To prepare stearic acid-based lopinavir (LPV) loaded solid lipid nanoparticles (SLNs) using a hybrid design and compare in-vivo performance of optimized formulation with marketed LPV/ritonavir (RTV) coformulation. METHODS: LPV SLNs were prepared by hot melt emulsion technique and optimized using Plackett-Burman design and Box-Behnken design. Physical characterization studies were conducted for the optimized SLNs. Comparative oral pharmacokinetic studies and tissue distribution studies of optimized SLNs and LPV/RTV coformulation were done in Wistar rats. In-vitro metabolic stability and intestinal permeability studies for LPV SLNs were undertaken to elucidate the mechanism involved in the pharmacokinetic improvement of LPV. KEY FINDINGS: Optimized SLNs exhibited nanometeric size (223 nm) with high entrapment efficiency (83%). In-vitro drug release study of SLNs showed biphasic sustained release behaviour. Significant increase in oral bioavailability of LPV from LPV SLNs (5 folds) and LPV/RTV coformulation (3.7 folds) was observed as compared with free LPV. LPV SLNs showed better tissue distribution of LPV in HIV reservoirs than LPV/RTV coformulation. In-vitro studies demonstrated that SLNs provided metabolic protection of LPV and were endocytosized during absorption. CONCLUSIONS: SLNs enhanced oral bioavailability and improved distribution profile of LPV to HIV reservoirs and hence could be better alternative to LPV/RTV coformulation.
Asunto(s)
Inhibidores de la Proteasa del VIH/administración & dosificación , Lopinavir/administración & dosificación , Nanopartículas , Ritonavir/farmacocinética , Ácidos Esteáricos/farmacocinética , Distribución Tisular , Animales , Preparaciones de Acción Retardada , Combinación de Medicamentos , Sistemas de Liberación de Medicamentos , Estabilidad de Medicamentos , Endocitosis , VIH , Inhibidores de la Proteasa del VIH/farmacocinética , Humanos , Absorción Intestinal , Lípidos/farmacocinética , Lopinavir/farmacocinética , Masculino , Ratas WistarRESUMEN
Raloxifene HCl (RLX) shows low oral bioavailability (<2%) in humans due to poor aqueous solubility and extensive (>90%) metabolism in gut. Lipid nanoparticles (SLN) with glyceryl tribehenate were designed to enhance drug's oral bioavailability. Box-Bhenken design was used to optimize manufacturing conditions. Optimized SLN had particle size of 167±3nm and high encapsulation efficiency (>92%). Oral bioavailability of RLX from SLN was improved by 3.24 folds compared to free RLX in female Wistar rats. Both clathrin and caveolae mediated endocytosis pathways were involved in the uptake of SLN. Lymphatic transport inhibitor, cycloheximide significantly reduced oral bioavailability of SLN.
Asunto(s)
Portadores de Fármacos/química , Ácidos Grasos/química , Nanopartículas/química , Clorhidrato de Raloxifeno/administración & dosificación , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Administración Oral , Animales , Cromatografía Líquida de Alta Presión , Composición de Medicamentos , Estabilidad de Medicamentos , Femenino , Tamaño de la Partícula , Poloxámero/química , Clorhidrato de Raloxifeno/farmacocinética , Ratas Wistar , Moduladores Selectivos de los Receptores de Estrógeno/farmacocinética , Propiedades de Superficie , Distribución TisularRESUMEN
OBJECTIVES: The objective of this study was to explore potential drug-drug/food interactions of ciprofloxacin and grapefruit juice, known hepatic cytochrome P450 (CYP) 1A2 inhibitors, on single-dose oral pharmacokinetics of riluzole, a substrate of CYP 1A2 enzymes. METHODS: Pharmacokinetic parameters of riluzole were determined in Wistar rats after single-dose co-administration with ciprofloxacin and grapefruit juice. In-vitro metabolic inhibition studies using rat and human liver microsomes and intestinal absorption studies of riluzole in a rat everted gut-sac model were conducted to elucidate the mechanism of interaction. A validated HPLC method was employed to quantify riluzole in the samples obtained in various studies. KEY FINDINGS: Co-administration of ciprofloxacin with riluzole caused significant increase in systemic exposure of riluzole (area under the curve, maximum plasma concentration and mean residence time were found to increase). Co-administration of grapefruit juice with riluzole did not cause any significant difference in the pharmacokinetic parameters of riluzole. In-vitro metabolism studies demonstrated significant inhibition of riluzole metabolism when it was co-incubated with ciprofloxacin or grapefruit juice. No significant change was observed in apparent permeability of riluzole. CONCLUSIONS: Co-administration of ciprofloxacin with riluzole increases the systemic levels of riluzole and thereby the oral pharmacokinetic properties of riluzole while co-administration of grapefruit juice with riluzole has no significant effect.
Asunto(s)
Bebidas , Ciprofloxacina/farmacología , Citrus paradisi , Riluzol/farmacocinética , Animales , Área Bajo la Curva , Inhibidores del Citocromo P-450 CYP1A2 , Interacciones Farmacológicas , Interacciones Alimento-Droga , Absorción Intestinal/fisiología , Masculino , Permeabilidad , Ratas , Ratas WistarRESUMEN
OBJECTIVES: Atorvastatin (ATV) and cilostazol (CLZ) are often co-prescribed to treat conditions such as peripheral arterial disease. In the present study, the drug-drug interaction potential of multi-dose CLZ on both pharmacokinetics and the lipid-lowering ability of single-dose ATV is demonstrated. METHOD: The pharmacokinetic parameters of ATV were determined in Wistar rats after per-oral pre-treatment with CLZ for 7 days in order to assess the interaction potential between ATV and CLZ. In-vitro metabolic inhibition and everted gut sac studies were conducted to elucidate the mechanism of this interaction. Biochemistry analyser was used to estimate lipid profiles in Wistar rats. A validated LC-MS/MS method was employed to simultaneously quantify both ATV and CLZ in rat plasma matrix. KEY FINDINGS: A statistically significant increase in systemic exposure to ATV after a single dose was observed in CLZ pre-treated rats. In-vitro metabolism studies using rat liver microsome (RLM) demonstrated statistically significant inhibition of ATV metabolism when co-incubated with CLZ. No change in apparent permeability of ATV was observed in the presence of CLZ. The blood lipid profile study after ATV administration indicated a statistically significant decrease in total cholesterol, triglycerides and LDL-cholesterol. CONCLUSIONS: Multi-dose administration of CLZ influences the pharmacokinetics and lipid-lowering properties of ATV. Collectively, an apparent interaction between selected drugs was evident.
Asunto(s)
Ácidos Heptanoicos/farmacocinética , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacocinética , Pirroles/farmacocinética , Tetrazoles/farmacología , Vasodilatadores/farmacología , Animales , Atorvastatina , Colesterol/sangre , LDL-Colesterol/sangre , Cromatografía Líquida de Alta Presión , Cilostazol , Interacciones Farmacológicas , Ácidos Heptanoicos/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Masculino , Microsomas Hepáticos/metabolismo , Pirroles/farmacología , Ratas , Ratas Wistar , Espectrometría de Masas en Tándem , Tetrazoles/administración & dosificación , Triglicéridos/sangre , Vasodilatadores/administración & dosificaciónRESUMEN
Cilostazol (CLZ) and atorvastatin (ATV) are often co-prescribed to treat conditions such as peripheral arterial disease. In the present study, the drug-drug interaction potential of multi-dose ATV co-administration with CLZ on both pharmacokinetics and the anti-thrombotic property of CLZ is demonstrated. The pharmacokinetic parameters of CLZ (6 mg/kg, twice daily) were determined in male Wistar rats after 7 days co-administration with ATV (5 mg/kg, once daily) in order to assess the interaction potential between CLZ and ATV on chronic treatment. In vitro metabolic inhibition and everted gut sac studies were conducted to elucidate the mechanism of this interaction. Pharmacodynamic drug-drug interaction was evaluated on anti-thrombotic models including time to occlusion, platelet aggregation and rat tail bleeding time. A validated LC-MS/MS method was employed simultaneously to quantify both ATV and CLZ in rat plasma matrix. A statistically significant increase in systemic exposure (Css(max) by ~1.75 fold; AUC by ~3.0 fold) to CLZ was observed in ATV pre-treated rats. In vitro metabolism studies using liver microsomes (RLM and HLM) demonstrated statistically significant inhibition of CLZ metabolism when co-incubated with ATV. No change in apparent permeability of CLZ was observed in the presence of ATV. Atorvastatin showed a significant delay in artery occlusion time without altering CLZ's bleeding time and platelet aggregation profile. Collectively the results of these studies provide metabolic insight into the nature of drug-drug interaction between the selected drugs. Co-administration with ATV influences the pharmacokinetics and anti-thrombotic property of CLZ. A thorough clinical investigation is required before extrapolation of data to humans.
Asunto(s)
Anticolesterolemiantes/administración & dosificación , Fibrinolíticos/administración & dosificación , Ácidos Heptanoicos/administración & dosificación , Pirroles/administración & dosificación , Tetrazoles/administración & dosificación , Animales , Atorvastatina , Tiempo de Sangría , Arterias Carótidas/efectos de los fármacos , Arterias Carótidas/fisiología , Cilostazol , Interacciones Farmacológicas , Fibrinolíticos/sangre , Fibrinolíticos/farmacocinética , Absorción Intestinal , Masculino , Microsomas Hepáticos/metabolismo , Agregación Plaquetaria/efectos de los fármacos , Ratas , Ratas Wistar , Tetrazoles/sangre , Tetrazoles/farmacocinéticaRESUMEN
Lopinavir is a new specific and potent HIV-1 protease inhibitor. A simple and rapid Reverse Phase High-Performance Liquid Chromatographic method using UV detection was developed and validated for the analysis of lopinavir in rat plasma under isocratic conditions. The method involves a single step protein precipitation technique. The detector response was linear over the concentration range of 250 to 4000 ng mL (-1). High recovery ranging from 97.5 to 101.2 percent was obtained which precludes the use of internal standard. The developed method was validated as per standard guidelines. Validation of the developed method demonstrated accuracy, precision and selectivity of the proposed method. The drug was found to be stable under various processing and storage conditions. This rapid and cost-effective method was successfully applied in the estimation of lopinavir and determination of various pharmacokinetic parameters during post intravenous bolus administration of the drug in rats. The developed method can be suitably employed in preclinical pharmacokinetic evaluation of new formulations designed to improve the bioavailability of lopinavir.